Paper Details

  1. Home
  2. Paper Details

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.

Author: Ben-AriZiv, BruckRafael, Cohen-EzraOranit, DeutschLiat, GozlanYael, HouriInbal, IssacharAssaf, KatchmanHelena, MenachemYoram, MorOrna, ShiboletOren, ShlomaiAmir, VeitsmanElla, Zelber-SagiShira

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Hepatitis C virus (HCV) infection can lead to chronic liver disease and hepatocellular carcinoma. First-generation protease inhibitors (PI) + peg-interferon (pegIFN) and ribavirin (RBV) achieved SVR rates of 65-75% but had side effects. This study evaluated the safety and efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (3D) ± RBV in HCV genotype 1 patients who failed previous treatment with first-generation PIs.
Paper Details　
Original Abstract of the Article :
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. Treatment with first generation protease inhibitors (PI) + peg-interferon (pegIFN) and ribavirin (RBV) achieved sustained virologic response (SVR) rates of 65-75% but was associated with multi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126165/

データ提供：米国国立医学図書館（NLM）

Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir ± Ribavirin for Hepatitis C Treatment

In the quest to combat chronic liver disease, researchers are constantly seeking innovative approaches to conquer the formidable foe known as hepatitis C virus (HCV). This study explores the efficacy of a novel treatment regimen combining Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin (3D) in patients with HCV genotype 1 who have failed previous treatment with first-generation protease inhibitors.

The Promise of 3D Treatment for Hepatitis C

The study aims to evaluate the safety and efficacy of this innovative treatment regimen in a multi-center trial. The findings hold promise for patients who have not responded well to traditional therapies, offering a potential path towards sustained virologic response (SVR), the ultimate goal in HCV treatment.

A New Hope for Hepatitis C Patients

This research represents a beacon of hope for those battling hepatitis C. The 3D treatment regimen offers a new avenue for achieving SVR, bringing renewed optimism to the field of HCV treatment and potentially improving the lives of countless patients. It's like discovering a hidden spring in the desert, offering a source of hope and rejuvenation in a seemingly barren landscape.

Dr.Camel's Conclusion

In the ever-changing desert of medical research, finding effective treatments for chronic liver disease is a constant quest. This study offers a glimmer of hope for patients with HCV genotype 1 who have not responded to traditional therapies. The 3D treatment regimen holds the potential to improve patient outcomes and provide a path towards a healthier future. It's like finding a precious oasis in the vast expanse of the desert, offering a source of healing and renewal.

Date :
  1. Date Completed 2020-05-27
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

32245397

DOI: Digital Object Identifier

PMC7126165

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.